Clinical Trials

Clinical Trials for MTG1

Filter list of Clinical Trials

TopicTrial name of investigational drugClinical Trial ID(s)StatusOrphaCodeLink
Chronic Adrenal InsufficiencyA European Multi-Centre, Post-Authorization, Observation Study (Registry) of Patients with Chronic Adrenal Insufficiency
  • NCT01661387
  • Terminated
  • ORPHA101959
Adrenocortical carcinomaEfficacy of Adjuvant Mitotane Treatment (ADIUVO) (ADIUVO)
  • NCT00777244
  • ongoing
  • ORPHA1501
Primary AldosteronismDP13 - A Phase II Study in Patients With Primary Aldosteronism
  • NCT04007406
  • completed
  • ORPHA181415
PheochromocytomaPRESCRIPT - Phenoxybenzamine Versus Doxazosin in PCC Patients
  • NCT01379898
  • concluded
  • ORPHA276621
  • ORPHA29072
Pheochromocytoma and ParagangliomaMulticenter Pheochromocytoma and Paraganglioma Evaluation (MUPPET)
  • NCT03344016
  • ongoing
  • ORPHA276621
  • ORPHA29072
Pheochromocytoma and ParagangliomaFIRSTMAPPP, Genetic variants associated with increased susceptibility to thyroid cancer
  • NCT01371201
  • ongoing
  • ORPHA276621
  • ORPHA29072
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine TumoursA study of MK-6482 Monotherapy in advanced Pheochromocytoma/Paraganglioma (PPGL) and pancreatic neuroendocrine tumors (pNET)
  • MK6482-PN015
  • ongoing
  • recruiting
  • ORPHA276621
  • ORPHA29072
Congenital Adrenal HyperplasiaPREDEX
  • 15554888
  • recruiting
  • ORPHA418
Congenital Adrenal HyperplasiaA Phase III study of efficacy, safety and tolerability of Chronocort® compared with standard glucocorticoid replacement therapy in the treatment of congenital adrenal hyperplasia
  • NCT02716818
  • concluded
  • ORPHA418
Congenital Adrenal HyperplasiaOpen-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy (RESTORE)
  • NCT03532022
  • ongoing
  • ORPHA418
Congenital Adrenal HyperplasiaA Phase 2, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Pediatric Subjects With Congenital Adrenal Hyperplasia
  • NCT04045145
  • NBI-74788
  • starting
  • recruiting
  • ORPHA418
Congenital Adrenal HyperplasiaA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment - Protocollo: NBI- 74788-CAH2006 - Codice EudraCT: 2020-004381-19 - Promosso da: Neurocrine Biosciences, Inc.- riferimento pratica CE: 589/2021/Farm/AOUBo
  • NCT04806451
  • NBI-74788-CAH2006
  • Ongoing
  • ORPHA418
Congenital Adrenal HyperplasiaDIUR-006 : A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH Diurnal Limited
  • NCT03062280
  • EudraCT Number: 2015-005448-32
  • ongoing
  • ORPHA418
Congenital Adrenal HyperplasiaA Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects With Classic Congenital Adrenal Hyperplasia
  • NCT04457336
  • ongoing
  • ORPHA418
Congenital Adrenal HyperplasiaCAHtalyst study - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia,
  • NCT04490915
  • NBI-74788-CAH3003
  • ongoing
  • recruiting
  • ORPHA418
Congenital Adrenal HyperplasiaA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects With Classic Congenital Adrenal Hyperplasia
  • NCT04544410
  • ongoing
  • ORPHA418
Transition,paediatric chronic endocrine disordersGrowing up With the Young Endocrine Support System (YESS!) (YESS)
  • NCT04252001
  • ongoing
  • ORPHA418
  • ORPHA174590
  • ORPHA881
  • ORPHA95488
  • ORPHA85138
  • ORPHA754
  • ORPHA9571
  • ORPHA95494
Adrenal TumoursCHIRACIC -Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas (CHIRACIC)
  • NCT02364089
  • ongoing
  • recruiting
  • ORPHA443287
Adrenal TumoursFAMAIN
  • EudraCT Number: 2012-003604-13
  • ongoing
  • ORPHA443287
  • ORPHA1501
Adrenal TumoursCombined 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and 123I-Iodometomidate (123I-IMTO) Imaging for Adrenal Neoplasia.
  • NCT02010957
  • concluded
  • ORPHA443287
  • ORPHA1501
Adrenal TumoursStructured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield (SERENDIPITY)
  • NCT02324647
  • completed
  • ORPHA443287
  • ORPHA1501
Adrenal TumoursGRADIENT; A phase 3, randomized, double-blind, placebo-controlled study of the efficacy and safety of Relacorilant
  • NCT04308590
  • ongoing
  • ORPHA443287
  • ORPHA553
Cushing SyndromeLOGICS: A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome (Levoketoconazole).
  • NCT03277690
  • concluded
  • ORPHA553
  • ORPHA99892
  • ORPHA99893
Cushing SyndromeAn Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
  • NCT03606408
  • ongoing
  • ORPHA553
  • ORPHA99892
  • ORPHA99893
Cushing SyndromeAn Open-Label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome
  • NCT03621280
  • COR-2017-OLE
  • ongoing
  • ORPHA553
  • ORPHA99892
  • ORPHA99893
McCune- Albright SyndromeMCRN007 (D6992C00044) - An Open-Label, Non-Comparative Trial To Evaluate The Safety, Efficacy And Pharmacokinetics Of FASLODEX™ (Fulvestrant) In Girls With Progressive Precocious Puberty Associated With Mccune Albright Syndrome
  • NCT00278915
  • ongoing
  • ORPHA562
Adrenal InsufficiencyOptimising Steroid Replacement in Patients With Adrenal Insufficiency (Plenadren)
  • NCT03282487
  • completed
  • ORPHA85138
  • ORPHA199296
  • ORPHA
  • 199299
Cushing SyndromeGRACE-2
  • NCT03604198
  • CORT125134-452
  • 2018-001616-30
  • ongoing
  • ORPHA99892
  • ORPHA96253
  • ORPHA99889
Cushing SyndromeGlucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant
  • NCT03697109
  • CORT125134-455
  • NL68116.078.18
  • ongoing
  • ORPHA99892
  • ORPHA96253
  • ORPHA99889
Adrenocortical CarcinomaACC: ADIUVO II o ACACIA: Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
  • NCT03723941
  • ongoing
  • ORPHA1501
Pheochromocytoma/Paraganglioma, pancreatic neuroendocrine tumorsA Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)
  • NCT04924075
  • MK6482- PN015
  • Ongoing
  • ORPHA573163
  • ORPHA97253
TopicTrial name of investigational drugClinical Trial ID(s)StatusOrphaCodeLink
Last update: May 19, 2022 on 11:02

An overview of all Clinical Trials can be found here.